Disclosure Of First-Time Adoption [Text Block]

Ascelia Pharma - Filing #689421

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31
Disclosure of first-time adoption [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity	180 859 SEK	—	—	—	—	– SEK	533 732 SEK	34 871 SEK	972,000 SEK	180 859 SEK	678 747 SEK	—	—	—	—	405 827 SEK	678 831 SEK	—	307 834 SEK	—	307 834 SEK	—	254,000 SEK	34 576 SEK	– SEK	—	—	—	286 491 SEK	– SEK	493 731 SEK	236 056 SEK	28 697 SEK	119,000 SEK	236 056 SEK
Comprehensive income	—	– SEK	130 504 SEK	131 223 SEK	– SEK	—	—	—	—	—	—	130 504 SEK	718,000 SEK	– SEK	– SEK	—	—	125 768 SEK	—	135,000 SEK	—	– SEK	—	—	—	– SEK	125 768 SEK	125 903 SEK	—	—	—	—	—	—	—
Profit (loss)	—	– SEK	131 223 SEK	131 223 SEK	– SEK	—	—	—	—	—	—	131 223 SEK	– SEK	– SEK	– SEK	—	—	125 903 SEK	—	– SEK	—	– SEK	—	—	—	– SEK	125 903 SEK	125 903 SEK	—	—	—	—	—	—	—